TY - JOUR
T1 - Oral Semaglutide in the Management of Type 2 DM
T2 - Clinical Status and Comparative Analysis
AU - Bandyopadhyay, Ilora
AU - Dave, Sunny
AU - Rai, Amita
AU - Nampoothiri, Madhavan
AU - Chamallamudi, Mallikarjuna Rao
AU - Kumar, Nitesh
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers
PY - 2022/2
Y1 - 2022/2
N2 - BACKGROUND: In the incretin system, Glucagon-like peptide-1 (GLP-1) is a hormone that inhibits the release of glucagon and regulates glucose-dependent insulin secretion. In type 2 diabetes, correcting the impaired incretin system using GLP-1 agonist is a well-defined therapeutic strategy. OBJECTIVES: This review article aims to discuss the mechanism of action, key regulatory events, clinical trials for glycaemic control, and comparative analysis of semaglutide with the second-line antidiabetic drugs. DESCRIPTION: Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with enhanced glycaemic control in diabetes patients. In 2019, USFDA approved the first oral GLP-1 receptor agonist, semaglutide, to be administered as a once-daily tablet. Further, recent studies highlight the ability of semaglutide to improve Glycemic control in obese patients with a reduction in body weight. Still, in clinical practice, in the type 2 DM treatment paradigm, the impact of oral semaglutide remains unidentified. This review article discusses the mechanism of action, pharmacodynamics, key regulatory events, and clinical trials regarding glycaemic control. CONCLUSION: The review highlights the comparative analysis of semaglutide with the existing second- line drugs for the management of type 2 diabetes mellitus by stressing its benefits and adverse events.
AB - BACKGROUND: In the incretin system, Glucagon-like peptide-1 (GLP-1) is a hormone that inhibits the release of glucagon and regulates glucose-dependent insulin secretion. In type 2 diabetes, correcting the impaired incretin system using GLP-1 agonist is a well-defined therapeutic strategy. OBJECTIVES: This review article aims to discuss the mechanism of action, key regulatory events, clinical trials for glycaemic control, and comparative analysis of semaglutide with the second-line antidiabetic drugs. DESCRIPTION: Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with enhanced glycaemic control in diabetes patients. In 2019, USFDA approved the first oral GLP-1 receptor agonist, semaglutide, to be administered as a once-daily tablet. Further, recent studies highlight the ability of semaglutide to improve Glycemic control in obese patients with a reduction in body weight. Still, in clinical practice, in the type 2 DM treatment paradigm, the impact of oral semaglutide remains unidentified. This review article discusses the mechanism of action, pharmacodynamics, key regulatory events, and clinical trials regarding glycaemic control. CONCLUSION: The review highlights the comparative analysis of semaglutide with the existing second- line drugs for the management of type 2 diabetes mellitus by stressing its benefits and adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85126389238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126389238&partnerID=8YFLogxK
U2 - 10.2174/1389450122666210901125420
DO - 10.2174/1389450122666210901125420
M3 - Article
C2 - 34468297
AN - SCOPUS:85126389238
VL - 23
SP - 311
EP - 327
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 3
ER -
